Biotechnology platforms
Biotechnology platforms apply biological systems to produce medicines, diagnostics, materials and agricultural products. They expand response capacity for health threats while introducing dual-use and biosafety concerns. Biotechnology and Biosecurity stewards this page for the Nexus Consortium.
- 01InstitutionThe Global Centre for Risk and Innovation (GCRI)
- 02Service levelR0: information and enquiries
- 03In briefThe short answer
- 04The methodWhat biotechnology platforms covers
- 05Reference practiceBiotechnology is governed by biosafety, biosecurity and responsible-use frameworks
- 06In systemic risk workPlatform capacity is preparedness
- 07Applied inPlatforms that apply this method
GCRI · Institution · service level R0
The short answer.
Biotechnology platforms apply biological systems to produce medicines, diagnostics, materials and agricultural products. Biotechnology capacity shapes how quickly countermeasures can be produced in a crisis. In the Nexus Consortium, Biotechnology and Biosecurity stewards its canonical page, and 2 other platforms apply it, including Food Nexus and Health Nexus.
Systemic exposure in the Gulf.
Where people and networks concentrate, the exposure through which shocks travel between systems, shown for the Gulf as an example geography for this subject.
What biotechnology platforms covers.
- 01
Core methods
genetic engineering; bioprocess design; high-throughput screening; diagnostic assay development; vaccine platform development; biosafety risk assessment.
- 02
Data and instruments
laboratory automation systems; bioreactor process data; clinical trial registries; genomic databases; manufacturing quality records.
- 03
Validation
Products are evaluated through staged preclinical and clinical testing and manufacturing quality controls. Regulatory review and independent replication check claims.
- 04
Limits
Scale-up from laboratory to production often fails or takes time. Containment and oversight can lag behind technical capability.
- 05
Use in risk decisions
Biotechnology capacity shapes how quickly countermeasures can be produced in a crisis. Its supply chains and dual-use potential are part of biosecurity planning.
Biotechnology is governed by biosafety, biosecurity and responsible-use frameworks.
| Reference | What it sets |
|---|---|
| WHO Laboratory Biosafety Manual | Risk-based biosafety |
| WHO responsible life sciences framework | Dual-use governance |
| Cartagena Protocol | Living modified organisms |
| Biological Weapons Convention | Prohibition and confidence-building measures |
This page covers capacity and oversight only.
Platform capacity is preparedness.
Biotechnology platforms (diagnostics, vaccine and therapeutic manufacturing) determine how quickly countries can respond to outbreaks and crop diseases. Systemic analysis looks at geographic concentration of capacity and at oversight arrangements, not at laboratory methods.
- Map manufacturing concentration for countermeasures.
- Assess regulatory reliance arrangements that speed approvals.
- Review oversight capacity alongside research capacity.
- Oversight work sits on Biotechnology and Biosecurity.
Platforms that apply this method.
Who maintains this page.
Biotechnology and Biosecurity stewards biotechnology platforms: it keeps this description current and reviews how the method is applied across the platforms.
Terms used on this page.
Each term as this page uses it. Where a standard-setting body defines the term, the wording follows that body.
| Term | Definition |
|---|---|
| Marker-assisted selection | Breeding that uses DNA markers linked to desired traits to select plants or animals more quickly and accurately. |
| Gene editing | Techniques such as CRISPR that make targeted changes to an organism's DNA; regulators differ on how they classify the products. |
| Living modified organism | An organism with a novel combination of genetic material obtained through modern biotechnology, as the Cartagena Protocol defines it. |
| Platform technology | A reusable production method, such as mRNA, that can be adapted to a new pathogen. |
Where this page's references lead.
The bodies and documents this page is read against. Status and editions change; each link goes to the issuing body.
Where this page leads across the Consortium.
Questions and answers.
Why does one institution host every method page?
How do I suggest a correction to a method page?
Around GCRI.
Start with an enquiry.
The current service level is R0: information and enquiries. An enquiry receives a reference and names the next step; applications, payments, compute allocations and registrations open only when their team, terms and review capacity exist.